Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cambridge Antibody Technology Group -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (373)	6/5/2003 12:58:08 PM
From: keokalani'nui	Respond to of 625

Adjunctive Use of Antifibrotic Agents Geoffrey P. Schwartz, MD, and Steven J. Gedde, MD The use of antimetabolite drugs has emerged as an important adjunct to glaucoma filtration surgery, specifically for high-risk cases. Trabeculectomy is designed to lower intraocular pressure by allowing the passage of aqueous humor from the anterior chamber to the subconjunctival space. The main source of failure for filtering surgery results from fibroblast proliferation and subsequent scar formation at the surgical site. [Huge Snip] Dr. Schwartz is a clinical glaucoma fellow at the Bascom Palmer Eye Institute. Dr. Gedde is an associate professor and Residency Program director at the Bascom Palmer Eye Institute. revophth.com